GLPwatch
Victoza for Obstructive sleep apnea
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCVictoza (liraglutide) is not FDA-approved for obstructive sleep apnea, and any use for this condition is off-label or investigational. Research includes studies on liraglutide’s effects on weight loss and sleep apnea severity, but these findings do not establish approval for the condition.
AI summary of the sources below.
| Drug | Victoza (liraglutide) |
|---|---|
| Condition | Obstructive sleep apnea |
| Approval status | Investigational / off-label |
| Research papers | 14 |
Victoza is not FDA-approved for obstructive sleep apnea; the research below reflects investigational or off-label study only.
Research on liraglutide for obstructive sleep apnea (14)
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
- Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.
- Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
- An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.
- Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
- Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
- Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.
- Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats.
- Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling.
- Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results.
- Liraglutide innovations: a comprehensive review of patents (2014-2024).
- Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.